Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rifabutin-containing Triple Therapy for H. pylori Rescue
NCT05874544Phase 4Completed
- Sponsor
- Shanghai Jiao Tong University School of Medicine
- Start
- May 2023
- Primary completion
- Jan 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of rifabutin in Helicobacter pylori infection (3 arms), sponsored by Shanghai Jiao Tong University School of Medicine. Primary endpoint: Helicobacter pylori eradication rate. Started May 2023; status: completed.
02
Drugs
rifabutin
03
Conditions
Helicobacter pylori infection
Beyond the preview
Go deeper on NCT05874544.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05874544.